34 results:
11. Rehabilitation  
Neurorehabilitation after stroke This page includes some information that is intended for registered users only. If you would like to access this information please login.Trailer…  
12. Registration  
Not registered yet? – please register here  
13. Data Privacy  
Privacy and Cookie Policy Version as of 25 May 2018 1. Introduction EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach am Attersee, Austria, of-fice@everpharma.com ("EVER"), respects your…  
14. Terms of Use  
Terms of Use Last updated: 11.04.2018 1. Scope of Agreement 1.1. The use of the services on the non-public product sites on www.cerebrolysin.com ("Website") is offered to you by EVER Neuro…  
15. EVER Partners  
EVER Partners In the scope of the business relationship with EVER Pharma and/or other companies of the EVER company group, personal data of customers, prospective customers, suppliers…  
16. Disease  
DiseaseStroke has become the second leading cause of long-term disability and the second cause of death worldwide.1 Annually, 15 million people suffer a stroke. Of these, 5 million die and…  
17. Prescribing Information  
Prescribing Information CerebrolysinAbbreviated Prescribing Information - Cerebrolysin Name of the medicinal product:  Cerebrolysin - Solution for injection. …  
18. Mode of Action  
Mode of Action of Cerebrolysin Cerebrolysin is a neurotrophic peptidergic drug with multimodal pharmacological properties indicated for the treatment of acute and chronic CNS disorders. The…  
19. Safety  
1 Heiss 2012, Stroke. 43:630-636.Safety of Cerebrolysin Cerebrolysin is safe and well tolerated! The experience with Cerebrolysin during many years of clinical application, the…  
20. About Cerebrolysin  
About Cerebrolysin Cerebrolysin is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and…  

Search results 11 until 20 of 34